Abstract:Human islet amyloid polypeptide (hIAPP or amylin) is a causative agent in pancreatic amyloid deposits found in patients with type 2 diabetes. The aggregation of full-length hIAPP(1-37) into small oligomeric species is increasingly believed to be responsible for cell dysfunction and death. However, rat IAPP (rIAPP(1-37)), which differs from hIAPP in only six of 37 residues, loses its aggregation ability to form toxic amyloid species. Atomic details of the effect of sequence on the structure and toxicity between the amyloidogenic, toxic hIAPP peptide and the nonamyloidogenic, nontoxic rIAPP peptide remain unclear. Here, we probe sequence-induced differences in structural stability, conformational dynamics, and driving forces between different hIAPP and rIAPP polymorphic forms from monomer to pentamer using molecular dynamics simulations. Simulations show that hIAPP forms from trimer to pentamer exhibit high structural stability with well-preserved in-register parallel beta-sheet and the U-bend conformation. The hIAPP trimer appears to be a smallest minimal seed in solution. The stabilities of parallel hIAPP oligomers increase with the number of peptides. Conversely, replacement of hIAPP sequence by rIAPP sequence causes a significant loss of favorable interpeptide interactions in all rIAPP oligomers, destabilizing the C-terminal beta-sheet, turn conformation, and overall stability. A less beta-sheet-rich structure and a disturbed U-shaped topology exert a large energy penalty on the self-assemble of the rIAPP peptides into highly ordered, in-register beta-sheet-rich protofibrils and fibrils, which explains the nonamyloidogenic activity of rIAPP. Moreover, the absence of interior water within the U-turn region in the well-packed higher-order hIAPP oligomers, not in the poorly packed rIAPP oligomers, also stabilizes peptide association. This work provides atomic details of the sequence-structure relationship between the amyloidogenic hIAPP and its analogues such as the nonamyloidogenic rIAPP and some mutants, which could help in the development of novel therapeutic agents to block the formation of toxic hIAPP oligomeric species for type 2 diabetes.

Drugging Disordered Proteins by Conformational Selection to Inform Therapeutic Intervention

Multi-Scaled Explorations of Binding-Induced Folding of Intrinsically Disordered Protein Inhibitor IA3 to Its Target Enzyme

Binding Cavities and Druggability of Intrinsically Disordered Proteins.

Diffusing protein binders to intrinsically disordered proteins

Influence of Force Field Choice on the Conformational Landscape of Rat and Human Islet Amyloid Polypeptide

Conservation of Potentially Druggable Cavities in Intrinsically Disordered Proteins

Rational Drug Design Targeting Intrinsically Disordered Proteins

Ligand clouds around protein clouds: a scenario of ligand binding with intrinsically disordered proteins.

A Small Molecule Causes a Population Shift in the Conformational Landscape of an Intrinsically Disordered Protein.

Structure-Based Inhibitor Design for the Intrinsically Disordered Protein C-Myc

Sequence-specific targeting of intrinsically disordered protein regions

Molecular Driving Force of a Small Molecule-Induced Protein Disorder-Order Transition

Stabilities and Structures of Islet Amyloid Polypeptide (IAPP22-28) Oligomers: from Dimer to 16-Mer.

Molecular Dynamics Simulation on the Inhibition Mechanism of Peptide-Based Inhibitor of Islet Amyloid Polypeptide (iapp) to Islet Amyloid Polypeptide (Iapp(22-28)) Oligomers

Comparative molecular dynamics study of human islet amyloid polypeptide (IAPP) and rat IAPP oligomers.

Dynamics of the Conformational Transitions During the Dimerization of an Intrinsically Disordered Peptide: A Case Study on the Human Islet Amyloid Polypeptide Fragment

Precise Generation of Conformational Ensembles for Intrinsically Disordered Proteins via Fine-tuned Diffusion Models

Structure Characterization of a Disordered Peptide Using In-Droplet Hydrogen Deuterium Exchange Mass Spectrometry and Molecular Dynamics

Converting the Amyloidogenic Islet Amyloid Polypeptide into a Potent Nonaggregating Peptide Ligand by Side Chain-to-Side Chain Macrocyclization

Identification of Electrostatic Hotspots at the Binding Interface of Amylin and InsulinDegrading Enzyme: A Structural and Biophysical Investigation

A Case Study of Disulfide-Bond Impact on the Intrinsically Disordered Amyloid Beta